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Abstract
Stanniocalcin-1 (STC-1) is a pro-survival factor that protects tissues against stressors, such as
hypoxia and inflammation. STC-1 is co-expressed with the endometrial receptivity markers, and
recently endometrial STC-1 was reported to be dysregulated in endometriosis, a condition linked
with endometrial progesterone resistance and inflammation. These features are also common
in the endometrium in women with polycystic ovary syndrome (PCOS), the most common
endocrine disorder in women. Given that women with PCOS present with subfertility, pregnancy
complications, and increased risk for endometrial cancer, we investigated endometrial STC-1
expression in affected women. Endometrial biopsy samples were obtained from women with
PCOS and controls, including samples from overweight/obese women with PCOS before and
after a 3-month lifestyle intervention. A total of 98 PCOS and 85 control samples were used in
immunohistochemistry, reverse-transcription polymerase chain reaction, or in vitro cell culture.
STC-1 expression was analyzed at different cycle phases and in endometrial stromal cells (eSCs)
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for STC-1 expression. The findings indicate that STC-1 expression is not steroid hormone mediated
although secretory-phase STC-1 expression was blunted in PCOS. Lower expression seems to be
related to attenuated STC-1 response to stressors in PCOS eSCs, shown as downregulation of
protein kinase A activity. The 3-month lifestyle intervention did not restore STC-1 expression in
PCOS endometrium. More studies are warranted to further elucidate the mechanisms behind the
altered endometrial STC-1 expression and rescue mechanism in the PCOS endometrium.
Summary sentence
Endometrial expression of STC-1 in the secretory phase is blunted in women with PCOS, suggest-
ing impaired protection against stress.
Key words: stanniocalcin-1, polycystic ovary syndrome, human endometrium, primary cell culture, endometrial
stromal cells, hypoxia, stress, lifestyle intervention
Introduction
Stanniocalcin-1 (STC-1) is a 56-kD homodimeric cellular glycopro-
tein that carries out autocrine and paracrine regulatory functions
with pleiotropic rather than classical endocrine hormonal effects
[1, 2]. Mammalian STC-1 is considered to be a pro-survival factor,
protecting against hypoxic, hypercalcemic, and ischemic damage,
suppressing inflammatory responses, and reducing oxidative stress
[3–6]. STC-1 has been detected in several human tissues, including
human endometrium, and its tissue expression fluctuates during the
menstrual cycle. Levels of STC-1 are high in mid-secretory-phase
endometrium (MSE) [7–9], and the high-expression levels coincide
with the receptivity markers related to the window of implantation
(WOI) [10]. Even though STC-1 knockout mice have been shown
to be fertile, STC-1 expression has been reported to be downregu-
lated during the mid-secretory phase in women with unexplained
infertility and in women with endometriosis, a condition under-
pinned by perturbed progesterone signal transduction and chronic
inflammation [8]. Furthermore, the results of several studies indi-
cate a role for STC-1 in cancer progression, including endometrial
cancer [11–13].
Given that STC-1 modulates hypoxic and inflammatory
responses by serving as a protective factor against these stressors,
the role of STC-1 in human endometrium is worth exploring.
Hypoxia in mammalian endometrium modifies the estrogen- and
progesterone-driven decidualization process, thus contributing to
the process of embryo implantation [14–16]. Furthermore, hypoxic
and inflammatory responses in human endometrium are robust,
especially during endometrial shedding [17], and their involvement
in endometrial cancer progression has also been noted [18, 19].
Therefore, dysregulated expression of STC-1 in human endometrium
could induce a more stressful environment for the implanting embryo
and eventually lead to chronic endometrial stress with impaired
protection against deoxyribonucleic acid (DNA) damage and cancer
[4, 20–22].
Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder in women of reproductive age, affecting
approximately 8–12% of this population. The syndrome is
characterized by oligo-anovulation, hyperandrogenism, and dysreg-
ulated metabolism [23]. All these characteristics may also affect
endometrial receptivity and induce endometrial cancer in time.
Indeed, women with PCOS have been shown to have an increased
risk of pregnancy complications such as miscarriage, preeclampsia,
and premature delivery but also a higher risk of endometrial cancer
[24–28]. Whether dysregulated STC-1 expression is one of the
mediating factors of these adverse outcomes in PCOS has yet to be
established.
Given that accumulation of stress factors can be detected in
the endometrium of women with PCOS, likely altering embryo
implantation and placental formation and promoting endometrial
cancer, investigation of the possible endometrial rescue mechanism
is of importance. In the present study, our primary aim was to
investigate endometrial STC-1 expression in women with PCOS in
different cycle phases and after steroid hormone exposure. Second, as
STC-1 has been previously shown to be triggered by cyclic adenosine
monophosphate (cAMP) and hypoxia, we used them as in vitro
stress tests for endometrial stromal cells (eSCs) to investigate STC-1
outcomes. As for the mechanism, cAMP-mediated protein kinase A
(PKA) activity was also evaluated. Last, we investigated the effect of
lifestyle intervention on STC-1 expression in women with PCOS.
Materials and methods
Study subjects and tissues
All biopsy specimens were collected using an endometrial suction
curette (Pipet Curet; CooperSurgical, USA). The distribution of the
samples used in each experiment is presented in Figure 1.
Samples from Oulu University Hospital. Endometrial biopsy samples
for cycle phase-dependent STC-1 expression and in vitro studies were
obtained from the Department of Obstetrics and Gynecology, Oulu
University Hospital, Oulu, Finland. All subjects were Caucasian and
had not used any hormonal medication for at least 3 months prior to
the sampling. The control women (n = 64) were healthy and reported
regular menstrual cycles with no indication of having PCOS. For all
experiments, body mass index (BMI) values were matched for both
study groups. The mean BMI of the controls was 24.2 ± 2.6 kg/m2,
and the mean age was 35.0 ± 5.9 (range 23–42) years. Women
with PCOS (n = 69) were selected from the hospital records by
tracing their former PCOS diagnoses established by a gynecologist or
reproductive endocrinologist using Rotterdam criteria. Their mean
BMI was 24.8 ± 3.3 kg/m2, and their mean age was 34.2 ± 3.8 (range
26–41) years.
The samples used in immuno-scoring and whole biopsy analyses
were collected in 2013–2019. The biopsies were taken on cycle
days (cd) 6–10 (proliferative phase, PE), luteinizing hormone (LH)
peak + 2–4 days (early secretory phase, ESE), LH + 7–9 days (MSE),
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Figure 1. Endometrial tissue samples used in each experiment. The samples obtained from the Karolinska Institutet (ntotal = 50) comprised 21 samples from
controls and 29 samples from women with PCOS. These samples were obtained during cd 6–8 and 21–23. Fourteen of the PCOS samples were obtained before
and after 3-month lifestyle intervention. Samples obtained from Oulu University Hospital were taken at the various cd of the menstrual cycle based on LH testing
(ntotal = 133). There were 64 control samples and 69 from women with PCOS.
peak (LH + 0) was confirmed with a urinary ovulation prediction
test (Clearblue Advanced Digital Ovulation Test kit). The corpus
luteum and secretory phase were also confirmed by a gynecologist
with an ultrasound on the day of the biopsy. The histology was
dated by a pathologist. Women with PCOS with amenorrhea were
only included in the PE endometrium group, and for them, no
ovulation tracing was done. The samples used in in vitro testing were
obtained in PE.
Samples from Karolinska Institutet. To investigate STC-1 expression
in women with PCOS and in controls, we used samples (PCOS
n = 29, controls n = 21) derived from a study conducted previously
(2008–2012) at the Women’s Health Research Unit of Karolin-
ska University Hospital, Karolinska Institutet, Stockholm, Sweden
[29, 30]. All women with PCOS fulfilled all three Rotterdam criteria,
with a mean BMI of 31.5 ± 8.8 kg/m2 and a mean age of 28.3 ± 5.1
(range 19–38) years. The controls were age and BMI matched:
mean BMI 27.9 ± 7.7 kg/m2; mean age 30.2 ± 5.8 (range 18–
38) years. The two study groups were further divided according
to BMI: BMI ≤ 27 kg/m2 (normal weight/overweight PCOS and
control; nN-PCOS = 11, nN-Ctrl = 11) or >27 kg/m2 (overweight/obese
PCOS and control, nO-PCOS = 18, nO-Ctrl = 10) on the basis of the
results of prior studies regarding the threshold for insulin resistance
[31, 32]. All women with PCOS and BMI > 27 kg/m2 presented
with ovulatory dysfunction, and all control women had regular
menstrual cycles with no indication of having PCOS. All women
were Caucasian, non-smokers, and free of any hormonal treatment
for at least 3 months prior to the sampling. Endometrial biopsy
samples were obtained during a single menstrual cycle between cd
6–8 (PE) and 21–23 (secretory, SE).
Samples from the lifestyle intervention study. The intervention part of
the study concerning obese women with PCOS has already been
published [29, 30]. Briefly, 15 women in this group underwent a
3-month lifestyle intervention program aimed at weight reduction
[29, 33]. Before and after this period, the women were examined
on cd 6–8 and 21–23 after spontaneous or medroxyprogesterone
acetate-induced menstruation (10 mg/day for 7 days). For the present
study, samples from 14 women were available both before and after
intervention.
Ethics approval
All participants gave written informed consent. The study protocols
and sample collection were approved by the ethics committees of
Oulu University Hospital, Oulu, Finland, and Karolinska Institutet,
Stockholm, Sweden. The experiments were conducted in accordance
with the principles of the Declaration of Helsinki.
Immunohistochemistry
All samples were fixed with formalin and embedded in paraf-
fin. Sections of endometrial biopsy samples (4 μm) were deparaf-
finized and washed. Antigen retrieval was performed with citrate
buffer in a microwave oven at 800 W for 2 min and 150 W
for 10 min. Neutralization of endogenous peroxidase was per-
formed in peroxidase-blocking solution (Dako S2023) for 5 min.
Sections were then incubated with anti-STC-1 (Atlas Antibodies;
HPA023918) in antibody diluent (Dako S2023) for 5 min at room
temperature, followed by incubation with Envision polymer (Dako
K5007, Denmark) for 30 min. Peroxidase activity was induced with
3, 3’-diaminobenzidine (DAB) working solution (DAKO K5007)
that was added to the slides. The slides were rinsed with distilled
water, counterstained in hematoxylin for 15 s, and then mounted
with mounting medium. Negative staining was performed on two
samples using Phosphate-buffered saline (PBS) buffer instead of
primary antibody. An Aperio ImageScope (Leica Biosystems, USA)
microscope was used to evaluate and photograph the slides. Semi-
quantitative evaluation of immunohistochemistry was performed
by three independent observers (MKh, RKA, and AH) who were
blinded to the identity of the slides; they used a grading system,
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intensity and numbers of stained cells were graded on the following
simple numeric scale: 0 = negative, 1 = faint, 2 = moderate, and
3 = intense. Average values obtained by the three observers are
presented.
Isolation and culture of endometrial stromal cells
Endometrial stromal cells were prepared using a previously described
optimized protocol [34, 35]. The technique produces a pure culture
of eSCs, as confirmed previously by vimentin [36]. The eSCs were
cultured in growth medium (phenol red-free medium at a 3:1 ratio
with high-glucose Dulbecco Modified Eagle Medium (DMEM): a
modified basal medium (MCDB)-105, 0.676 mM sodium pyruvate,
10% (v/v) charcoal-stripped fetal bovine serum (FBS), 1% (w/v)
penicillin–streptomycin mix, gentamicin at 50 mg/mL, and insulin at
5 mg/mL). The media were replaced twice weekly until the desired
confluency was reached prior to the experiment.
Steroid hormone exposure and decidualization
Estrogen and progesterone exposure to test stromal cell decidualization
capacity. One-hundred thousand (105) eSCs were plated in 12 well
plates in duplicate and cultured in growth medium (3:1 high-glucose
DMEM/MCDB-105, 0.75 mM sodium pyruvate, 50 mg/mL gen-
tamycin, and 10% FBS). When the cells showed 100% confluency,
they were incubated for 24 h in low-serum medium (2% FBS)
prior to the decidualization experiment. For these cultures, eSCs
from the control women (n = 12) and from the women with PCOS
(n = 13) were treated with 0.1% ethanol vehicle, and a combination
of estradiol (E2; 10 nM, Sigma-Aldrich, Finland) and progesterone
(P4; 1 μM, Sigma-Aldrich) in low-serum medium for 14 days. The
culture medium and cells were collected at 0 h and at 14 days after
E2 and P4 exposure to check the decidualization marker.
Steroid hormones, 8-bromo-cAMP, and hypoxia
challenges as triggers for STC-1
Estrogen and progesterone exposure. One-hundred thousand (105)
eSCs from the control women (n = 12) were treated with 0.1%
ethanol vehicle, in a combination of E2 (10 nM, Sigma-Aldrich)
and P4 (1 uM, Sigma-Aldrich) in low-serum medium for 48 h and
14 days. The cells were collected after 48 h and 14 days to check
STC-1 expression.
5 Alpha-dihydrotestosterone exposure. One hundred thousand (105)
eSCs from control women (n = 6) and women with PCOS (n = 6) were
plated in six well plates in duplicate and cultured until confluent.
After 24 h of starvation in low-serum medium, cells were treated
with 0.1% ethanol vehicle, and E2 (10 nM, Sigma-Aldrich) alone or
a combination of E2 and 5α-dihydrotestosterone (DHT; 100 nM,
Sigma-Aldrich) in low-serum medium for 24 h [37]. The culture
medium and cells were collected at 0 h and 24 h after steroid
hormone (E2 or E2 + DHT) exposure.
8-Bromo-cAMP challenge. One hundred thousand (105) eSCs
(nctrl = 12, nPCOS = 13) were plated in duplicate in 12 well plates.
After the cells had reached confluency, they were maintained in low-
serum medium for 24 h followed by an 8-bromo-cAMP (8-Br-cAMP;
0.5 mM, Sigma-Aldrich) challenge for 96 h [8, 38, 39]. The culture
media and cells were collected after 96 h of incubation with 8-Br-
cAMP and tested for STC-1 Ribonucleic acid (RNA) and protein
expression.
Hypoxia challenge. One hundred thousand (105) eSCs (nCtrl = 12,
nPCOS = 13) were plated in 12 well plates in duplicate and cultured in
growth medium. At confluency, the cells were grown in low-serum
medium for 24 h prior to treatment with 10% FBS-supplemented
DMEM/F-12 medium under hypoxic conditions (1% O2, 5% CO2
and 94% N2; InVivo2 400 Hypoxia work station SCI-tive N;
Ruskinn Technology Ltd., Bridgend, UK) or normoxic conditions
(21% O2, 5% CO2, and 74% N2) for 24 h and 48 h as previously
described [40]. The cells and supernatants were collected, and each
experiment was repeated.
RNA isolation, complementary DNA synthesis, and
quantitative reverse-transcription polymerase chain
reaction
RNA from cultured eSCs and endometrial tissue samples was iso-
lated using the QIAcube automated RNA isolation system according
to the manufacturer’s instructions (Qiagen RNeasy Mini kit: (Hilden,
Germany) including DNase treatment). Five hundred nanograms
of RNA was converted to complementary DNA (cDNA) (Thermo
Fisher cDNA synthesis kit: thermos Fisher Scientific Baltics UAB,
Lithunia). Duplicate messenger RNAs (mRNAs) were pooled from
each set of treatments. The comparative Ct method was used to
obtain the relative expression according to the Livak 2−Ct method
(Real-Time PCR, Bio-Rad, Finland) [41]. Expression of the target
gene was normalized to that of glyceraldehyde 3-phosphate dehydro-
genase, which is stably expressed in endometrial tissue, as previously
shown [40, 42]. The primer sequences for quantitative reverse-
transcription polymerase chain reaction (qRT-PCR) are presented in
Supplementary Table S1.
Enzyme-linked immunosorbent assay for STC-1
STC-1 proteins from the culture media (E2/P4-, 8-Br-cAMP-, and
hypoxia-treated) were measured according to the manufacturer’s
instructions (R&D systems; Antibodies-online.com). All samples
were assayed in duplicate, and a standard curve was run for each
experiment.
Protein kinase A activity assay
Endometrial eSCs from both study groups (n = 4/group) were plated
in six well plates and cultured until confluency and thereafter grown
in a low-serum medium for 24 h. Subsequently, they were treated
with 0.5 mM 8-Br-cAMP or 0.25% dimethyl sulfoxide (DMSO)
for monitoring basal activity of PKA for 96 h. The cells were then
lysed on ice as previously described [43], and the supernatants were
collected.
The total protein concentration in obtained lysates was
established using a Coomassie Plus (Bradford) Assay Kit (Thermo
Scientific) according to the manufacturer’s instructions. Within
each experiment, the total protein concentration of all collected
lysates was equalized by suitable dilution with kinase assay
buffer (50 mM 4-(2-Hydroxyethyl)-1-piperazine ethanesulfonic
acid (HEPES) pH 7.5, 150 mM NaCl, 0.005% Tween-20, 5 mM
dithiothreitol, and 0.5 mg/mL Bovine serum albumin (BSA) fraction
V). The assay was carried out as previously described [44]; the final
total concentrations of ARC-1139 and H89 (Cayman Chemical)
were 2 nM and 2–4 μM, respectively. The incubation times for
binding and displacement were 30–60 min, and the time-delayed
photoluminescence was measured using a PheraStar microplate
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Figure 2. Expression of STC-1 in human endometrium. (A) Quantitative reverse-transcription polymerase chain reaction analysis of endometrial samples
from healthy control women (gray bar) and women with PCOS (black bar) collected at cd 7–10 (nctrl = 7, nPCOS = 7), LH + 2–4 (nctrl = 5, nPCOS = 5), LH + 7
(nctrl = 7, nPCOS = 7), and LH + 10–12 (nctrl = 5, nPCOS = 7) revealed a significant increase in endometrial STC-1 gene expression from the PE (cd 7–10)
toward the LSE (LH + 10–12) in both control samples (P = 0.003) and samples from women with PCOS (P = 0.001). Data are presented as mean ± standard
error of the mean (SEM). (B) Semi-quantitative immunohistochemistry data on STC-1 protein expression in different endometrial cell compartments (stromal
cells (stroma), luminal epithelium (LE), and GE) from control samples assessed at cd 8–10 (n = 6), LH + 2–4 (n = 7), LH + 7–9 (n = 6), and LH + 10–12
(n = 7) revealed the highest expression in the LSE (LH + 10–12) compared with the PE (cd 8–10; P = 0.022) and MSE (LH + 7–9; P = 0.001) in stromal cells,
whereas (C) there was no significant difference between the cycle phases in cells from women with PCOS. (D) STC-1 expression in different cycle phases
studied by immunohistochemistry in control women (a–h) and in women with PCOS (i–l). (a) PE (cd 8–10); (b) ESE (LH + 2–4); (c) MSE (LH + 7–9); (d) LSE
(LH + 10–12). Higher magnification images from control women (40×) of GE shows that in PE, STC-1 is localized to the GE cells (e), and in ESE it is concentrated
in the apical parts (f) from which it is gradually secreted into the lumen during the MSE (g) and LSE (h). The stromal STC-1 staining was weak in PE (m) and
significantly stronger in LSE (n), but in PCOS, the staining intensity was similar across the cycle phases. (o) LSE stroma of a PCOS case; (p) negative control
staining.
(300–360) nm, emission 675 (50) nm, integration start 60 μs, and
integration time 400 μs. For each lysate, the difference in the ARC-
1139 signal prior to and after the addition of H89 was calculated.
Within a single independent experiment, the values calculated for
different lysates were then normalized to the value calculated for
lysate from a sample of healthy eSCs treated with 0.25% DMSO
(PKA activity set to 100%). The results of all measurements were
then pooled.
Statistical evaluation
Statistical analyses were performed using non-parametric one-way
analysis of variance (Kruskal–Wallis test) for differences among more
than two groups, whereas differences between two groups were
examined using the Mann–Whitney test. For the PKA data analysis,
an unpaired t-test with the Welchs´ correction was carried out. The
results are presented as mean ± SEM. Values of P value less than 0.05
were considered statistically significant. IBM SPSS statistics software
version 22.0 and GraphPad Prism 6 were used for statistical analyses
and for preparing images, respectively.
Results
Cyclic expression of STC-1 in endometrium from
women with polycystic ovary syndrome and
non-polycystic ovary syndrome controls
The LH-timed endometrial tissue analyses from controls and women
with PCOS showed highest STC-1 expression at LSE compared
with that at PE (P = 0.003 and 0.001, respectively). However, in
Karolinska samples obtained from younger women with more severe
PCOS phenotype and higher BMI, no such increase was observed
(Figures 2A, 3A and B).
In line with the mRNA results, STC-1 protein staining became
stronger toward LSE in control women (Figure 2D, a–d). In more
detail, intracellular STC-1 was detected in glandular epithelium
(GE) during PE, and it gradually became concentrated in the
apical part of the epithelial cells and secreted into the lumen in
the LSE (Figure 2D, e–h 40×). During PE, only weak, punctuated
STC-1 staining was detected in the stroma (Figure 2D, m),
whereas stromal cells undergoing decidual transformation in LSE
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control samples. This accumulation was missing in PCOS samples
(Figure 2D, n and o). As for the semi-quantitative protein data, STC-
1 expression was higher in the stroma LSE vs PE in the controls
(P = 0.022), with no difference in the epithelial cells in different cycle
phases (Figure 2B). Differently from controls, PCOS endometrium
showed blunted STC-1 protein expression with no differences
in STC-1 between cycle phases in different cell compartments
(Figure 2C).
Cyclic expression of STC-1 according to BMI in control
vs polycystic ovary syndrome
In controls, in both women with BMI ≤ 27 kg/m2 (N-Ctrl) and
those with BMI > 27 kg/m2 (O-Ctrl), the STC-1 expression was
higher in secretory-phase samples at cd 21–23 compared with
expression in the PE at cd 6–8 (P = 0.044 and 0.001, respectively;
Figure 3A and B). Women with PCOS failed to present elevated
STC-1 expression toward the secretory phase in both BMI groups
(cd 6–8 vs cd 21–23; Figure 3A and B).
Confirmation of endometrial stromal cells
decidualization and steroid hormone exposure
for induction of STC-1
All control and PCOS eSCs used in in vitro experiments were able to
decidualize successfully after E2/P4 exposure for 14 days according
to insulin-like growth factor-1 and prolactin measurements (data not
shown).
To find out whether STC-1 expression in eSCs is related to
steroid hormone actions, cultures of eSCs from control women were
subjected to a combination of E2 and P4 for 48 h and 14 days.
No increased expression of STC-1 was observed after either time
point (Supplementary Figure S1A). Therefore, no further testing was
executed with the PCOS samples.
To assess the role of androgens in eSC STC-1 expression in
controls and women with PCOS, the eSCs were treated for 24 h
with E2 alone or with a combination of E2 and DHT. No significant
change in STC-1 expression was detected in eSCs in either study
group, confirming that steroid hormones do not directly induce STC-
1 in eSCs (Supplementary Figure S1B).
STC-1 expression during 8-bromo-cAMP challenge in
polycystic ovary syndrome vs control endometrial
stromal cells
Cultures of eSCs from control women and women with PCOS were
exposed to 8-Br-cAMP for 96 h to induce STC-1 expression. STC-
1 mRNA was highly upregulated (∼140 fold) in cultured eSCs from
control subjects, while eSCs from women with PCOS showed signifi-
cantly lower expression (P = 0.001; Figure 4A). Quantitative protein
measurements from the growth media revealed similar stromal cell
basal secretion of STC-1 in the two study groups. However, 8-Br-
cAMP-induced STC-1 expression was lower in the eSCs from women
with PCOS vs controls, supporting the qRT-PCR findings (P = 0.01;
Figure 4B).
Basal and cyclic adenosine
monophosphate-dependent protein kinase
A activity in polycystic ovary syndrome vs control
endometrial stromal cells
To establish whether differences in STC-1 expression in control
women and women with PCOS could be explained by differences
in PKA activity (basal or 8-Br-cAMP induced), eSCs from control
Figure 3. Cyclic expression of STC-1 in women with BMI ≤ 27 kg/m2 (N)
and BMI > 27 kg/m2 (O) in controls and in women with PCOS. (A) STC-1
expression during cd 6–8 and 21–23 in controls with BMI ≤ 27 kg/m2 (N-Ctrl,
n = 11 and n = 7, respectively) and in women with PCOS and BMI ≤ 27 kg/m2
(N-PCOS, n = 5 and n = 5, respectively). The control women presented with
elevated STC-1 expression at cd 21–23 compared with cd 6–8 (P = 0.044),
whereas there was no significant increase in STC-1 expression toward cd 21–
23 in women with PCOS. (B) STC-1 expression at cd 6–8 and 21–23 in controls
with BMI > 27 kg/m2 (O-Ctrl, n = 5 and n = 5, respectively) and in women with
PCOS and BMI > 27 kg/m2 (O-PCOS, n = 8 and n = 15, respectively). Control
women presented with elevated STC-1 expression at cd 21–23 compared with
cd 6–8 (P = 0.001), but in women with PCOS the effect was again blunted.
subjects and women with PCOS were treated with 8-Br-cAMP
or DMSO for 96 h. The eSCs from women with PCOS showed
lower basal and 8-Br-cAMP-induced PKA activity at 96 h
compared with the controls (P = 0.001 and 0.006, respectively;
Figure 4C).
STC-1 expression during hypoxia challenge in
polycystic ovary syndrome vs control endometrial
stromal cells
The eSCs from control women and from women with PCOS were
subjected to hypoxic (1% O2) conditions for 24 h and 48 h.
Hypoxic conditions induced STC-1 mRNA expression in control
eSCs—8-fold and 2.5-fold higher expression at 24 h and 48 h,
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Figure 4. (A) STC-1 mRNA expression, (B) protein expression, and (C)
PKA activity analysis in response to 8-Br-cAMP challenge in cultured eSCs
obtained from control women and from women with PCOS. (A) Expression
of STC-1 mRNA in stromal cells from control women (n = 10, gray bars) and
women with PCOS (n = 12, black bars) after treatment with 0.5 mM 8-Br-cAMP
for 96 h. STC-1 expression was blunted in the stromal cells obtained from
women with PCOS (P = 0.001) compared with the controls. (B) Similarly,
STC-1 protein secretion from stromal cells into culture media after 96 h of
0.5 mM 8-Br-cAMP administration was lower (P = 0.01) in women with PCOS
(n = 12, black bars) compared with controls (n = 10, gray bars). Basal STC-1
secretion, however, did not differ between the study groups. (C) PKA activity
was significantly higher in stromal cells from control women (n = 4, gray
bars) compared to women with PCOS (n = 4, black bars; P = 0.006) after
96 h of 0.5 mM 8-Br-cAMP treatment. Interestingly, stromal cells from control
women also presented with higher basal PKA activity than the stromal cells
from women with PCOS (P = 0.001). Data are shown as mean values ± SEM.
was impaired in stromal cells from women with PCOS at both
time points compared with the controls (24 h: P < 0.0001, 48 h:
P = 0.001; Figure 5A). STC-1 expression was lower in the eSC
culture media from women with PCOS compared with that from the
controls (P = 0.001) after 48 h of exposure to hypoxia (Figure 5B),
supporting the mRNA data.
Figure 5. Expression of (A) STC-1 mRNA and (B) protein in cultured eSCs
during hypoxia challenge (1% oxygen). (A) STC-1 mRNA expression of eSCs
obtained from control women (n = 12, gray bars) and from women with PCOS
(n = 13, black bars) after 24 hand 48 h of hypoxic challenge. The stromal cells
from women with PCOS showed lower STC-1 mRNA expression at both 24 h
(P < 0.0001) and 48 h (P = 0.001). (B) STC-1 protein secretion into eSC culture
supernatant under normoxic (24 h) and hypoxic (24 and 48 h) conditions in
cells from healthy controls (n = 12, gray bars) and from women with PCOS
(n = 13, black bars). No significant changes were observed between the study
groups under normoxic or hypoxic conditions after 24 h. However, at 48 h,
the STC-1 response to hypoxia was blunted in stromal cells obtained from
women with PCOS compared with the cells from controls (P = 0.001). Data
are shown as mean ± SEM.
Effect of weight and lifestyle intervention on
STC-1 expression
Control women with BMI > 27 kg/m2 (O-Ctrl) presented higher
secretory phase STC-1 expression compared with the controls with
BMI ≤ 27 kg/m2 (P = 0.047). However, no such difference was
observed in women with PCOS (Figure 6A). Interestingly, 3-month
lifestyle intervention did not restore endometrial STC-1 mRNA
expression in the O-PCOS group (P = 0.223; Figure 6B).
Discussion
This is the first study to investigate STC-1 expression in the
endometrium of women with PCOS. We used both in vivo and
in vitro approaches and found that women with PCOS presented
with reduced STC-1 expression during the secretory phase of the
menstrual cycle. Furthermore, stromal cells from women with PCOS
showed blunted STC-1 responses when challenged with 8-Br-cAMP
and hypoxia. These results suggest that women with PCOS have
altered STC-1 expression even during the secretory phase and in
response to stress that may result in a defective rescue mechanism
against endometrial stressors. Lifestyle intervention was not able to
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Figure 6. Effects of weight and lifestyle intervention on endometrial STC-1
expression. (A) Endometrial STC-1 mRNA expression at cd 21–23 in con-
trol women with BMI ≤ 27 kg/m2 (N-Ctrl, n = 11) and in controls with
BMI > 27 kg/m2 (O-Ctrl, n = 5), showing increased endometrial STC-1
expression in O-Ctrl women (P = 0.047). No significant difference in STC-1
mRNA expression was found between the two weight groups of women with
PCOS (N-PCOS, n = 5 vs O-PCOS, n = 15). (B) Relative expression of STC-1 on
cd 21–23 in women with PCOS and BMI > 27 kg/m2 before (O-PCOS, before
intervention, n = 14) and after (O-PCOS, after intervention, n = 14) 3-month
lifestyle intervention. Lifestyle intervention failed to restore endometrial STC-
1 expression. All values are means ± SEM.
STC-1 has been shown to be expressed not only in human
endometrium during the WOI but also in the placenta, suggesting
a role in maternal–fetal interaction [45–47]. Since STC-1 knockout
mice have been shown to be fertile, STC-1 seems to serve as a
pro-survival factor modifying the endometrial environment rather
than as an imperative factor for implantation [48–50]. In line with
previous reports showing increased endometrial STC-1 secretion
toward the secretory phase [8], we detected increased endometrial
STC-1 expression toward MSE and LSE not only in the control
group but also in the LH-timed PCOS samples. Interestingly, the
endometrial samples from younger women with PCOS with a more
severe phenotype and higher BMI failed to show an increase in
STC-1 expression toward the secretory phase. Moreover, STC-
1 protein expression in LH-timed in vivo samples was increased
from PE to LSE stromal cells only in control women and not in
PCOS, possibly indicating a defect in the stromal cells in women
with PCOS. Given that STC-1 has been suggested to serve as a
protective factor against oxidative stress and inflammation [51],
and the fact that the endometrium in women with PCOS has been
shown to display an abnormal inflammatory profile [35], the blunted
STC-1-mediated rescue mechanism may be of clinical importance.
The fact that blunted STC-1 was shown in the secretory phase
endometrium suggests that progestin treatment or endogenous
progesterone may not be sufficient to reduce the risk of endometrial
dysfunction in PCOS, as commonly thought. On a related note,
although the eSCs were able to decidualize in response to steroid
hormones in both study groups, the steroid hormones per se
did not stimulate STC-1 expression, in line with data published
by Aghajanova et al. [8]. Moreover, even though many of the
metabolic derangements in PCOS are driven by hyperandrogenism,
the difference in STC-1 expression in stromal cells was not promoted
by androgens, as shown by the experiment with DHT exposure.
As women with PCOS presented with an altered STC-1 expres-
sion in in vivo samples, next we challenged eSCs with cAMP, a
trigger for STC-1 expression. We observed that stromal cells from
controls presented a strong increase in STC-1 in response to 8-Br-
cAMP, whereas the expression was blunted in PCOS samples. As
cAMP action has been described to occur through activation of the
canonical PKA signaling pathway, a blunted cAMP-induced STC-
1 response may suggest a defect in this signaling cascade [8, 52].
Therefore, PKA signaling was tested in stromal cells from women
with PCOS and from controls. The experiment confirmed, for the
first time, blunted cAMP-mediated PKA signaling in stromal cells in
women with PCOS.
In the present study, hypoxia was not able to trigger STC-1 in
stromal cells from women with PCOS, in contrast to controls. In
addition, secreted protein levels were lower in the stromal cell culture
media from women with PCOS. Again, this might be crucial, given
that hypoxia is an important factor in embryo implantation and
cancer development; however, it has to be restricted for successful
maternal–fetal interaction [15, 16]. Moreover, STC-1 has been iden-
tified as one of the hypoxia-responsive genes involved in hypoxia-
driven angiogenesis in various cancer cell types; thus, blunted STC-1
could promote hypoxia-mediated cancer progression [53, 54].
The role of obesity was assessed in the present study using
the samples obtained from Karolinska Institutet. The data showed
increased STC-1 expression from PE to SE and higher STC-1 expres-
sion in overweight/obese control women compared to women with
BMI < 27 kg/m2. Interestingly, no such increases from PE to SE or
with overweight/obesity were detected in endometrial samples from
women with PCOS. The elevated STC-1 expression in the secretory
phase in controls with BMI ≥27 kg/m2 suggests that overweight/obe-
sity might be one of the stress factors inducing endometrial STC-1,
a rescue mechanism that seems to be missing in PCOS.
Women with PCOS are prone to systemic metabolic alterations
with dysregulated glucose uptake and lipid metabolism and elevated
low-grade inflammation. In PCOS, these alterations are commonly
promoted by obesity; thus, lifestyle intervention is recommended
as the first-line therapy for affected women (as also stated by the
recently published International PCOS Guideline) [23]. We therefore
assessed STC-1 expression before and after a 3-month lifestyle
intervention. Previously, this intervention was reported to normal-
ize menstrual cycles and to improve endometrial steroid receptor
expression in women with PCOS [29, 30]. The intervention was
not, however, able to restore STC-1. As lifestyle interventions are
commonly known to be expensive and difficult due to high drop-out
rates, other approaches should also be considered. Some studies have
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profiles in PCOS endometrium [55, 56]. Whether this also applies to
STC-1 remains to be investigated.
In the present study, we utilized rare endometrial tissue samples
to assess STC-1 expression in women with PCOS. To increase the
number of samples, we were able to pool samples from two study
centers including well-characterized patients, LH-timed samples, and
the possibility to separate women by BMI and assess the effects of
an intervention. Power calculations were not feasible as no previous
data on STC-1 in cases of PCOS were available. Limitations include
the fact that patient recruitment for endometrial studies is known to
be challenging, and for this reason, the number of endometrial tissue
samples remains limited. In addition, the samples from Karolinska
Institutet were collected in 2008–2012 and stored as RNA after
extraction. However, we estimated the quality of the samples to
be acceptable for the methods used for the present study. We are
also aware of the difficulty of comparing in vitro results with in
vivo findings. Moreover, even though we tested androgen effects
in an in vitro environment, we could not consider the roles of
systemic hyperandrogenism or hyperinsulinemia, both common in
PCOS, in an in vitro environment. As for cellular STC-1 signaling,
more profound pathway analyses and mechanistic approaches are
warranted.
Conclusion
This is the first study reporting blunted STC-1 expression in the
endometrium of women with PCOS. We also report decreased STC-1
expression in response to 8-Br-cAMP and hypoxic challenge in PCOS
stromal cells in vitro. The basal and cAMP-driven PKA pathway acti-
vation was significantly lower in women with PCOS compared with
controls, which may explain the STC-1 outcome in affected women.
Defective endometrial STC-1 expression in PCOS may result in an
impaired rescue mechanism, promoting endometrial dysfunction or
even cancer in these women (Supplementary Figure S2).
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